IMOGAM RABIES-HT (Sanofi Pasteur Inc.)


Welcome to the PulseAid listing for the IMOGAM RABIES-HT drug offered from Sanofi Pasteur Inc.. This pharmaceutical is classified as a PLASMA DERIVATIVE. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same PLASMA DERIVATIVE drug type category.
LABELER NAME / MANUFACTURER: Sanofi Pasteur Inc.
NON-PROPRIETARY NAME: HUMAN RABIES VIRUS IMMUNE GLOBULIN
SUBSTANCE NAME: HUMAN RABIES VIRUS IMMUNE GLOBULIN
TYPE: PLASMA DERIVATIVE
PHARMA CLASS:
ROUTE: INTRAMUSCULAR
DOSAGE FORM: INJECTION, SOLUTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 1984-04-27
END MARKETING DATE: 0000-00-00


IMOGAM RABIES-HT PLASMA DERIVATIVE Details:

Item DescriptionIMOGAM RABIES-HT from Sanofi Pasteur Inc.
LABELER NAME: Sanofi Pasteur Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 150([iU]/mL)
START MARKETING DATE: 1984-04-27
END MARKETING DATE: 0000-00-00
PRODUCT ID: 49281-190_0554e76f-a5a3-4480-998c-62bd4e40c0b8
PRODUCT NDC: 49281-190
APPLICATION NUMBER: BLA103932

Other HUMAN RABIES VIRUS IMMUNE GLOBULIN Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
GRIFOLS USA, LLCHYPERRAB
Sanofi Pasteur Inc.IMOGAM RABIES-HT